Bibliografía

1. Miyazawa I, Fujihara K, Itoyama Y. Eugene Devic (1858–1930). J Neurol 2002;249:351–2.
2. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–1489
3. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–7.
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–12.
5. Jacob A, Das K, Nicholas R, et al. Neuromyelitis optica (Devic’s disease) in the United Kingdom: epidemiology, clinical, radiological and therapy profile in the first 42 patients. In: American Academy of Neurology 57th Annual Meeting; April 9–16, 2005, Miami Beach, Florida. Abstract PO5.133.
6. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG.The clinical course of neuromyelitis optica (Devic’s syndrome).Neurology 1999; 53: 1107–14.
7. Ch’ien LT, Medeiros MO, Belluomini JJ, Lemmi H, Whitaker JN.Neuromyelitis optica (Devic’s syndrome) in two sisters.Clin Electroencephalogr 1982; 13: 36–39.
8. Yamakawa K, Kuroda H, Fujihara K, et al. Familial neuromyelitis optica (Devic’s syndrome) with late onset in Japan. Neurology 2000;55: 318–19.
9. O’Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI fi ndings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996; 60: 382–87.
10. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60: 848–53.
11. Pittock SJ, Weinshenker BG, Wijdicks EF. Mechanical ventilation and tracheostomy in multiple sclerosis.J Neurol Neurosurg Psychiatry 2004; 75: 1331–33.
12. Kurtzke JF. Cinical manifestations of multiple sclerosis. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology. Amsterdam:North-Holland; 1970: 161–216.
13. Milano E, Di Sapio A, Malucchi S, et al. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. Neurol Sci 2003;24:130–133.
14. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–127
15. Bergamaschi R, Tonietti S, Franciotta D, et al. Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis:differences in repeated cerebrospinal fluid examinations.Mult Scler 2004;10:2–4
16. de Seze J, Stojkovic T, Ferriby D, et al. Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002;197:57–61
17. Ebers GC, Paty DW. CSF electrophoresis in one thousand patients. Can J Neurol Sci 1980;7:275–280
18. McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index: a comparison and diagnostic applications. Brain 1990;113:1269–1289
19. Mandler RN, Davis LE, Jeff ery DR, Kornfeld M. Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993; 34: 162–68.
20. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica.Brain 2002; 125: 1450–61.
21. Mirsattari SM, Johnston JB, McKenna R, et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology 2001; 56: 317–23.
22. Lefkowitz D, Angelo JN. Neuromyelitis optica with unusual vascular changes. Arch Neurol 1984; 41: 1103–05.
23. Nakamura M, Endo M, Murakami K, Konno H, Fujihara K, Itoyama Y. An autopsied case of neuromyelitis optica with a large cavitary cerebral lesion. Mult Scler 2005; 11: 735–38.
24. Jacobs D, Roemer S, Weinshenker B, et al. The pathology of brain involvement in neuromyelitis optica spectrum disorder. Mult Scler 2006; 12: S155.
25. Pittock SJ, Lennon VA, Wingerchuk DM, Homburger HA, Lucchinetti CF, Weinshenker BG. The prevalence of non-organspecifi c autoantibodies and NMO-IgG in neuromyelitis optica (NMO) and related disorders. Neurology 2006; 66: A307.
26. Hummers LK, Krishnan C, Casciola-Rosen L, et al. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies.Neurology 2004; 62: 147–49.
27. Pittock SJ, Lennon VA, De Seze J, et al. Neuromyelitis optica spectrum disorders and non-organ-specific autoimmunity. Arch Neurol (in press).
28. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63: 964–68.
29. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005; 11: 617–21.
30. Agre P, Kozono D. Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett 2003; 555: 72–78.
31. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P,Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin 4 in rat brain. J Neurosci 1997; 17: 171–80.
32. Roemer SF, Parisi JE, Lennon VA, et al. Pattern specifi c loss of aquaporin 4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194–205.
33. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006; 77: 1073–75.
34. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390–396
35. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005; 11: 617–21.
36. Saiz A, Zuliani L, Blanco Y, et al, for the Spanish-Italian NMO study group. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 2007; published online April 2. DOI: 10.1007/s00415-007-0509-8.
37. Zuliani L, Lopez de Munain A, Ruiz Martinez J, Olascoaga J, Graus F, Saiz A. NMO-IgG antibodies in neuromyelitis optica: a report of 2 cases. Neurologia 2006; 21: 314–17.
38. Littleton ET, Jacob A, Boggild M, Palace J. An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica. Mult Scler 2006; 12: S156.
39. Jarius S, Franciotta D, Bergamaschi R, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68: 1076–77.
40. Okai AF, Muppidi S, Bagla R, Leist TP. Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica? Neurol Res 2006; 28: 354–59.
41. Mochizuki A, Hayashi A, Hisahara S, Shoji S. Steroidresponsive Devic’s variant in Sjogren’s syndrome. Neurology 2000;54:1391–1392
42. Krishnan AV, Halmagyi GM. Acute transverse myelitis in SLE. Neurology 2004;62:2087
43. Tellez-Zenteno JF, Remes-Troche JM, Negrete-Pulido RO, Davila-Maldonado L. Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging in six cases. Lupus 2001;10:851–856
44. Hummers LK, Krishnan C, Casciola-Rosen L, et al. Recurrent transverse myelitis associated with anti-Ro (SSA) autoantibodies. Neurology 2004;62:147–149
45. Lehnhardt FG, Impekoven P, Rubbert A, et al. Recurrent longitudinal myelitis as a primary manifestation of SLE. Neurology 2004;63:1976
46. Pittock SJ, Lennon VA, Wingerchuk DM, et al. The prevalence of non-organ-specific autoantibodies and NMOIgG in neuromyelitis optica (NMO) and related disorders. Neurology 2006;66:A307
47. Weinshenker BG, De Seze J, Vermersch P, et al. The relationship between neuromyelitis optica and systemic autoimmune disease. Neurology 2006;66:A380
48. Pittock SJ, Weinshenker BG, Wingerchuk D, et al. Autoimmune neurological accompaniments of neuromyelitis optica (NMO). Ann Neurol 2006;60:S41
49. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol 2006;13:655–658
50. Kister I, Gulati S, Boz C, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006;63:851–856
51. Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002; 125: 2460–68
52. Weinshenker BG, Wingerchuk DM, Nakashima I, Fujihara K, Lennon VA. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006; 5: 110–11.
53. Misu T, Kakita A, Fujihara K, et al. A comparative neuropathological analysis of Japanese cases of neuromyelitis optica and multiple sclerosis. Neurology 2005; 64: A39.
54. Matsuoka T, Matsushita T, Kawano Y, et al. Heterogeneity of aquaporin 4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130: 1206–23.
55. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2005;7:173–182
56. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143–146